Drugs / Abacavir/Lamivudine/Dolutegravir
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02067767 | Feb 2014 → Dec 2015 | HIV infectious disease | Nantes University Hospital | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Abacavir/Lamivudine/Dolutegravir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02067767 ↗ |
| Known as | ABC/3TC/DTG | “Abacavir/Lamivudine/Dolutegravir (ABC/3TC/DTG) offers simplification with a single pill per day” NCT02067767 ↗ |